Maypharm Launches METOO FILL HA FILLER, Metox botulinum toxin with a 2nd generation technological advantage
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
08
Mer, Mag

Maypharm Launches METOO FILL HA FILLER, Metox botulinum toxin with a 2nd generation technological advantage

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

(Adnkronos) - SEOUL, South Korea and NEW YORK, Aug. 15, 2023 /PRNewswire/ -- Maypharm CO, LTD, known as a Korean manufacturer, recently successfully launched Metox botulinum toxin with a 2nd generation technological advantage and meNnus PLA filler for collagen regeneration using only advanced technologies in the developed

products that are responsible for their safety and effectiveness. 

For many years, France, Germany, and USA have been considered constant leaders in the field of cosmetology and innovations in the creation of products for cosmetology market. But everything changed after the entry into the arena of South Korea, a country that has made a real revolution in the beauty industry, incorporating the use of innovative technologies into production, and introducing products to the world that has no analogues before. 

METOOFILL hyaluronic acid dermal filler (CE Approved), made by Maypharm CO, LTD, overcame the limitations of traditional hyaluronic acid cross-linking technology by using patented innovative three patented technologies. 

1. Microbead Monophasic Technology 

This patented technology increases the gel's durability with a homogeneous structure of HA particles that provides stable volume, outstanding cohesion, and migration resistance. 

2. Multi-stage Cross-linking Technology 

Metoo Fill goes through a three-stage high-rate DVS cross linking process that optimizes density, provides outstanding viscoelastic properties, flexibility and an improved injectability profile while retaining the biocompatibility and physical functionality of unmodified HA. 

3. Multi-degree Amphiphilic Purification 

After cross-linking, Metoo Fill goes through a multi-step purification process to completely neutralize the cross-linking agent using PBS solution, resulting in a network of HA chains with a purity of over 97%, as opposed to other products in the market with a purity up to 95%. 

As a result, the Metoo Fill series contains 4 lines with different gel parameters for various needs: Applying these three patented technologies, the products METOO FILL are longer-lasting, easily moldable, resulting in a very natural finish that will satisfy the client. 

For further details, please contact us at Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo. or visit our website, https://www.may-pharm.com/  

Photo - https://mma.prnewswire.com/media/2185792/METOO_FILL_HA_FILLER.jpgPhoto - https://mma.prnewswire.com/media/2185793/METOO_FILL_HA_FILLER2.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/maypharm-launches-metoo-fill-ha-filler-metox-botulinum-toxin-with-a-2nd-generation-technological-advantage-301900737.html  

 

Ho scritto e condiviso questo articolo
Author: Red AdnkronosWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.